Immunovia’s vision is to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
To develop and commercialise non-invasive blood tests, so that more patients can receive a timely diagnosis, that can lead to improved treatment outcomes.
Immunovia’s long-term goal is a 30% share of the US pancreatic cancer testing market for IMMray™ PanCan-d after reimbursement and widespread insurance coverage has been achieved.
We push innovation at the forefront to create a new generation of diagnostic tools that give clinicians better opportunity to diagnose cancer – early and with confidence.
Our goal is a world where all patients are properly diagnosed in time for appropriate treatment and better quality of life.
We have an opportunity to lead the way and drive change through breakthrough technology, clinical expertise and new thinking.
We are proud to continue the Swedish tradition of cutting-edge, life science innovation and will continue to display clinical and technical excellence in all things we do.
We are committed to revolutionizing cancer care for better patient management and improved survival.
